Table of contents


On 20 June 2005, orphan designation (EU/3/05/288) was granted by the European Commission to A Carlsson Research AB, Sweden, for 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine x HC1 for the treatment of Huntington's disease.

The sponsorship was transferred as follows:

  • to NSAB, Filial af NeuroSearch Sweden AB, Sverige, Denmark in July 2009;
  • to Teva Pharma GmbH, Germany, in April 2013;
  • to Teva GmbH, Germany, in November 2016;
  • to Clinical Technology Centre (Ireland) Limited, Ireland, in February 2019 and
  • to Granzer Regulatory Consulting & Services, Germany, in July 2020.

This medicine is now known as pridopidine hydrochloride.


Key facts

Active substance
4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1 (pridopidine hydrochloride)
Disease / condition
Treatment of Huntington’s disease
Date of first decision
EU designation number

Sponsor's contact details

Granzer Regulatory Consulting & Services
Kistlerhofstrasse 172c
81379 Munich
Tel. +49 8978 0689 829

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating